<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04936815</url>
  </required_header>
  <id_info>
    <org_study_id>UHIBerne</org_study_id>
    <nct_id>NCT04936815</nct_id>
  </id_info>
  <brief_title>Effectiveness of Echocardiographic Screening of Pregnant Women During Antenatal Care: a Cluster Randomized Crossover Trial</brief_title>
  <official_title>Effectiveness of Echocardiographic Screening of Pregnant Women During Antenatal Care: a Cluster Randomized Crossover Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Pilgrim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>B.P. Koirala Institute of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Non-obstetrical drivers of adverse pregnancy outcomes are underappreciated. Latent&#xD;
      structural heart disease may account for a substantial proportion of adverse pregnancy&#xD;
      outcomes in low-resource settings.&#xD;
&#xD;
      Objectives: (1) to assess the prevalence of structural heart disease among pregnant women in&#xD;
      Nepal; (2) to determine the effectiveness of echocardiographic screening of women during&#xD;
      antenatal care on maternal, fetal and neonatal outcomes; (3) to assess pregnancy outcomes in&#xD;
      women with structural heart disease.&#xD;
&#xD;
      Inclusion Criteria : Pregnant women ≥18 years presenting for the first visit of routine&#xD;
      antenatal care; written informed consent.&#xD;
&#xD;
      Exclusion Criteria : Women presenting to the hospital after delivery, women presenting&#xD;
      directly for delivery without previous antenatal care.&#xD;
&#xD;
      Methods: The study compares an experimental condition and a control condition in a cluster&#xD;
      randomized crossover design. There will be 4 periods of 5 months duration each and 2&#xD;
      conditions (experimental and control). Women in the experimental group will undergo&#xD;
      systematic echocardiographic screening for structural heart disease followed by&#xD;
      guideline-directed peripartum management. Women in the control arm will undergo routine&#xD;
      antenatal care.&#xD;
&#xD;
      Co-primary endpoints:&#xD;
&#xD;
        1. Maternal endpoint: The composite of maternal death, heart failure, and hospitalization&#xD;
           for cardiovascular reasons as assessed at the time of hospital discharge after delivery&#xD;
           or at 7 days after delivery&#xD;
&#xD;
        2. Offspring endpoint: The composite of fetal/neonatal death as assessed at the time of&#xD;
           hospital discharge after birth or at 7 days after birth, or APGAR Score &lt;7 as assessed&#xD;
           at 10 minutes after birth.&#xD;
&#xD;
      Secondary endpoints: heart failure, cardiac interventions (percutaneous mitral balloon&#xD;
      valvuloplasty), supraventricular tachycardia, atrial fibrillation, ventricular tachycardia,&#xD;
      thrombotic and thromboembolic complications, cerebrovascular event, postpartum haemorrhage,&#xD;
      preterm birth (&lt;37 weeks), and birthweight &lt;2500g.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The study compares an experimental condition and a control condition in a cluster randomized crossover design. There will be 4 periods of 5 months duration each and 2 conditions (experimental and control). Women in the experimental group will undergo systematic echocardiographic screening for structural heart disease followed by guideline-directed peripartum management. Women in the control arm will undergo routine antenatal care.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Co-primary endpoint</measure>
    <time_frame>Hospital discharge after delivery or 7 days after delivery.</time_frame>
    <description>Maternal endpoint: The composite of maternal death, heart failure, and hospitalization for cardiovascular reasons.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Co-primary endpoint</measure>
    <time_frame>Hospital discharge after birth or 7 days after delivery (death); APGAR score as assesssed at 10 minutes after birth</time_frame>
    <description>Offspring endpoint: The composite of fetal/neonatal death as assessed at the time of hospital discharge after birth or APGAR Score &lt;7 as assessed at 10 minutes after birth.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoints:</measure>
    <time_frame>Hospital discharge after delivery or 7 days after delivery.</time_frame>
    <description>heart failure, cardiac interventions (percutaneous mitral balloon valvuloplasty), supraventricular tachycardia, atrial fibrillation, ventricular tachycardia, thrombotic and thromboembolic complications, cerebrovascular event, postpartum haemorrhage, preterm birth (&lt;37 weeks), and birthweight &lt;2500g.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6090</enrollment>
  <condition>Valvular Heart Disease</condition>
  <condition>Rheumatic Heart Disease</condition>
  <condition>Pregnancy Complications</condition>
  <arm_group>
    <arm_group_label>Echocardiographic screening</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Echocardiographic screening during the first antenatal visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Routine antenatal are</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Transthoracic echocardiography</intervention_name>
    <description>Transthoracic echocardiography for the detection of congenital or acquired structural heart disease.</description>
    <arm_group_label>Echocardiographic screening</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women ≥18 years presenting for the first visit of routine antenatal care&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women presenting to the hospital after delivery&#xD;
&#xD;
          -  Women presenting directly for delivery without previous antenatal care.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Surendra Uranw, MPH</last_name>
    <phone>00977 9842042705</phone>
    <email>surendra.uranw@bpkihs.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiology, Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Inselspital, Berne</investigator_affiliation>
    <investigator_full_name>Thomas Pilgrim</investigator_full_name>
    <investigator_title>Deputy Physician-in-Chief</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Heart Disease</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

